1.Boscaro C, Schimdt G, Cignarella A, Dal Maso L, Bolego C, Trevisi L. The antiangiogenic effect of digitoxin is dependent on a ROS-elicited RhoA/ROCK pathway activation. Biochem Pharmacol. 2024 Apr;222:116049.
2.Oliviero F, Baggio C, Favero M, Damasco AC, Boscaro C, Tietto D, Albiero M, Doria A, Ramonda R. Synovial Fluid from Patients with Osteoarthritis Shows Different Inflammatory Features Depending on the Presence of Calcium Pyrophosphate Crystals. Int J Mol Sci. 2023 Dec 27;25(1):393.
3.Boscaro C, Ramaschi GE, Trevisi L, Cignarella A, Bolego C. MiR-206 inhibits estrogen signaling and ovarian cancer cell migration without affecting GPER. Life Sci. 2023 Nov 15;333:122135.
4.Cignarella A, Boscaro C, Albiero M, Bolego C, Barton M. Post-Transcriptional and Epigenetic Regulation of Estrogen Signaling. J Pharmacol Exp Ther. 2023 Sep;386(3):288-297.
5.Albiero M, Ciciliot S, Rodella A, Migliozzi L, Amendolagine FI, Boscaro C, Zuccolotto G, Rosato A. and Fadini GP. Modulation of hematopoietic cell-derived oncostatin M and metabolic responses to high-fat diet in mice. Diabetes. 2023 Apr 1;72(4):483-495.
6.Baggio C, Luisetto R, Boscaro C, Scanu A, Ramonda R, Albiero M, Sfriso P, Oliviero F. Leucocyte Abnormalities in Synovial Fluid of Degenerative and Inflammatory Arthropathies. Int J Mol Sci. 2023 Mar 13;24(6):5450.
7.Baggio C, Boscaro C, Oliviero F, Trevisi L, Ramaschi G, Ramonda R, Bolego C, Cignarella A. Gender differences and pharmacological regulation of angiogenesis induced by synovial fluids in inflammatory arthritis. Biomed Pharmacother. 2022;152:113181.
8.Boscaro C, Baggio C, Carotti M, Sandonà D, Trevisi L, Cignarella A, Bolego C. Targeting of PFKFB3 with miR-206 but not mir-26b inhibits ovarian cancer cell proliferation and migration involving FAK downregulation. FASEB J. 2022;36(3):e22140.
9.Dama A, Baggio C, Boscaro C, Albiero M, Cignarella A. Estrogen receptor functions and pathways at the vascular immune interface. Int J Mol Sci. 2021; 22:4254.
10.Cignarella A, Fadini GP, Bolego C, Trevisi L, Boscaro C, Sanga V, Seccia TM, Rosato A, Rossi GP, Barton M. Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges. Cardiovasc Res. 2021 Mar 19: cvab096.
11.Boscaro C, Trenti A, Baggio C, Scapin C, Trevisi L, Cignarella A, Bolego C. Sex differences in the pro-angiogenic response of human endothelial cells: focus on PFKFB3 and FAK activation. Front Pharmacol. 2020; 11:587221.
12.Boscaro C, Carotti M, Albiero M, Trenti A, Fadini GP, Trevisi L, Sandonà D, Cignarella A, Bolego C. Non-genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells. FASEB J. 2020; 34:12768-84.
13.Trenti A, Boscaro C, Tedesco S, Cignarella A, Trevisi L, Bolego C, Effects of digitoxin on cell migration in ovarian cancer inflammatory microenvironment. Biochem Pharmacol. 2018; 154:414-23.
14.Trenti A*, Tedesco S*, Boscaro C*, Trevisi L, Bolego C, Cignarella A, Estrogen, angiogenesis, immunity and cell metabolism: solving the puzzle. Int J Mol Sci. 2018; 19:859.
15.Tedesco S, Zusso M, Facci L, Trenti A, Boscaro C, Belluti F, Fadini GP, Skaper SD, Giusti P, Bolego C, Cignarella A, Bis-demethoxycurcumin and its cyclized pyrazole analogue differentially disrupt lipopolysaccharide signaling in human monocyte-derived macrophages. Mediators Inflamm. 2018; 2018: 2868502.
16.Trenti A, Tedesco S, Boscaro C, Ferri N, Cignarella A, Trevisi L, Bolego C, The glycolytic enzyme PFKFB3 is invol